Katharine Peterson - 14 Feb 2026 Form 4 Insider Report for Acrivon Therapeutics, Inc. (ACRV)

Role
Chief Accounting Officer
Signature
/s/ Adam D. Levy, Attorney-in-Fact
Issuer symbol
ACRV
Transactions as of
14 Feb 2026
Net transactions value
-$189
Form type
4
Filing time
18 Feb 2026, 16:14:35 UTC
Previous filing
18 Nov 2025
Next filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Peterson Katharine Chief Accounting Officer C/O ACRIVON THERAPEUTICS, INC., 480 ARSENAL WAY, SUITE 100, WATERTOWN /s/ Adam D. Levy, Attorney-in-Fact 18 Feb 2026 0002022214

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACRV Common Stock Tax liability $189 -116 -2.8% $1.63 4,006 14 Feb 2026 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.